Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 5, 2012, Pages

  Lawler, Patrick R ^a   Lawler, Jack ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; CD47 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; THROMBOSPONDIN 1; THROMBOSPONDIN 2; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FYN PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; NITRIC OXIDE; PROTEIN KINASE FYN; THROMBOSPONDIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BIOAVAILABILITY; CELL CYCLE PROGRESSION; ENDOTHELIUM CELL; HUMAN; NONHUMAN; PHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; TUMOR MICROENVIRONMENT; CELL MOTION; CELL PROLIFERATION; DRUG ANTAGONISM; FORECASTING; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; FORECASTING; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; PROTO-ONCOGENE PROTEINS C-FYN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1; THROMBOSPONDINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867268459     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a006627     Document Type: Article

References (95)

1. Aboody KS, Najbauer J, Danks MK. 2008. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 15: 739-752.
2. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, Dimmeler S. 2003. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9: 1370-1376.
3. Anderson JC, Grammer JR, Wang W, Nabors LB, Henkin J, Stewart JE Jr., GladsonCL. 2007. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther 6: 454-462.
4. Andre N, Padovani L, Verschuur A. 2010. Metronomic chemotherapy: Back to the future! Drug News Perspect 23: 143-151.
5. Bagavandoss P, Wilks JW. 1990. Specific inhibition of endothelial cell proliferation by thrombospondin. Biochem Biophys Res Commun 170: 867-872.
6. Baker LH, Rowinsky EK, Mendelson D, Humerickhouse RA, Knight RA, Qian J, Carr RA, Gordon GB, Demetri GD. 2008. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 26: 5583-5588.
7. Bein K, Simons M. 2000. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 275: 32167-32173.
8. BenEzra D, Griffin BW, Maftzir G, Aharonov O. 1993. Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysaccharide. Invest Ophthalmol Vis Sci 34: 3601-3608.
9. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. 2003. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci 100: 12917-12922.
10. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. 2000. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886.
11. 1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J Biol Chem 279: 41734-41743.
12. Campbell NE, Greenaway J, Henkin J, Moorehead RA, Petrik J. 2010. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia 12: 275-283.
13. Chen H, Herndon ME, Lawler J. 2000. The cell biology of thrombospondin-1. Matrix Biol 19: 597-614.
14. Chi AS, Norden AD, Wen PY. 2009a. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics 6: 513-526.
15. Chi AS, Sorensen AG, Jain RK, Batchelor TT. 2009b. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist 14: 621-636.
16. Colombo G, Margosio B, Ragona L, Neves M, Bonifacio S, Annis DS, StravalaciM, Tomaselli S, Giavazzi R, Rusnati M, et al. 2010. Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: An integrated strategy for the development of new antiangiogenic compounds. J Biol Chem 285: 8733-8742.
17. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. 1997. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138: 707-717.
18. Dawson DW, Volpert OV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J, Bouck NP. 1999. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 55: 332-338.
19. Dome B, Timar J, Ladanyi A, Paku S, Renyi-Vamos F, Klepetko W, Lang G, Dome P, Bogos K, Tovari J. 2009. Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy. Crit Rev Oncol Hematol 69: 108-124.
20. Duda DG, Fukumura D, Jain RK. 2004. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med 10: 143-145.
21. Dudzinski DM, Michel T. 2007. Life history of eNOS: Partners and pathways. Cardiovasc Res 75: 247-260.
22. Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight RA, Humerickhouse RA, Qian J, Gordon GB, Figlin R. 2007. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 13: 6689-6695.
23. 2-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: A possible role for syndecan-4 proteoglycan. Matrix Biol 21: 311-324.
24. Folkman J. 1971. Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186.
25. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, Buerk DG, HuangPL, Jain RK. 2001. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci 98: 2604-2609.
26. Gao AG, Lindberg FP, Finn MB, Blystone SD, Brown EJ, Frazier WA. 1996. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem 271: 21-24.
27. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, BouckNP. 1990. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci 87: 6624-6628.
28. Gordon MS, Mendelson D, Carr R, Knight RA, Humerickhouse RA, Iannone M, Stopeck AT. 2008. A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. Cancer 113: 3420-3429.
29. Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J, Petrik J. 2007. Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 210: 807-818.
30. Greenaway J, Henkin J, Lawler J, Moorehead R, Petrik J. 2009. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther 8: 64-74.
31. Guo NH, Krutzsch HC, Inman JK, Shannon CS, Roberts DD. 1997. Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. J Pept Res 50: 210-221.
32. Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP. 1999. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 3: 147-158.
33. Hanahan D, Folkman J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
34. Haviv F, Bradley MF, Kalvin DM, Schneider AJ, Davidson DJ, Majest SM, McKayLM, Haskell CJ, Bell RL, Nguyen B, et al. 2005. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: Design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 48: 2838-2846.
35. Heroult M, Bernard-Pierrot I, Delbe J, Hamma-Kourbali Y, Katsoris P, BarritaultD, Papadimitriou E, Plouet J, Courty J. 2004. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. Oncogene 23: 1745-1753.
36. Hoekstra R, de Vos FY, Eskens FA, Gietema JA, van der Gaast A, Groen HJ, Knight RA, Carr RA, Humerickhouse RA, Verweij J, et al. 2005. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 23: 5188-5197.
37. Hoekstra R, de Vos FY, Eskens FA, de Vries EG, Uges DR, Knight R, Carr RA, Humerickhouse R, Verweij J, Gietema JA. 2006. Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination. Eur J Cancer 42: 467-472.
38. Hynes RO. 2009. The extracellular matrix: Not just pretty fibrils. Science 326: 1216-1219.
39. Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H, Makino K, Ikeda E, Takata S, Kobayashi K, Okada Y. 2002. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J 16: 219-221.
40. Iruela-Arispe ML. 2008. Regulation of thrombospondin1 by extracellular proteases. Curr Drug Targets 9: 863-868.
41. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. 1999. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 100: 1423-1431.
42. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD. 2005. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci 102: 13141-13146.
43. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD. 2006. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 281: 26069-26080.
44. Isenberg JS, Jia Y, Fukuyama J, Switzer CH, Wink DA, Roberts DD. 2007. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem 282: 15404-15415.
45. Isenberg JS, Pappan LK, Romeo MJ, Abu-Asab M, Tsokos M, Wink DA, FrazierWA, Roberts DD. 2008. Blockade of thrombospondin-1-CD47 interactions prevents necrosis of full thickness skin grafts. Ann Surg 247: 180-190.
46. Isenberg JS, Annis DS, Pendrak ML, Ptaszynska M, Frazier WA, Mosher DF, Roberts DD. 2009a. Differential interactions of thrombospondin-1,-2, and-4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chemo 284: 1116-1125.
47. Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD. 2009b. Regulation of nitric oxide signaling by thrombospondin 1: Implications for anti-angiogenic therapies. Nat Rev Cancer 9: 182-194.
48. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G. 2007. Angiogenesis inhibitor therapies: Focus on kidney toxicity and hypertension. Am J Kidney Dis 50: 203-218.
49. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. 2000. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6: 41-48.
50. Jimenez B, Volpert OV, Reiher F, Chang L, Munoz A, Karin M, Bouck N. 2001. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1. Oncogene 20: 3443-3448.
51. Kaur B, Brat DJ, Calkins CC, Van Meir EG. 2003. Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am J Pathol 162: 19-27.
52. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, Fogler WE, SimBK, Allred EN, Pirie-Shepherd, et al. 2001. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61: 7669-7674.
53. Koch M, Hussein F, Woeste A, Grundker C, Frontzek K, Emons G, HawighorstT. 2011. CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo. Breast Cancer Res Treat 128: 337-346.
54. Lawler JW, Slayter HS, Coligan JE. 1978. Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J Biol Chem 253: 8609-8616.
55. Maclauchlan S, Skokos EA, Agah A, Zeng J, Tian W, Davidson JM, Bornstein P, Kyriakides TR. 2009. Enhanced angiogenesis and reduced contraction in thrombospondin-2-null wounds is associated with increased levels of matrix metalloproteinases-2 and-9, and soluble VEGF. J Histochem Cytochem 57: 301-313.
56. Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, et al. 2007. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 30: 303-309.
57. Miao WM, Seng WL, Duquette M, Lawler P, Laus C, Lawler J. 2001. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-β-dependent and-independent mechanisms. Cancer Res 61: 7830-7839.
58. Milkiewicz M, Hudlicka O, Brown MD, Silgram H. 2005. Nitric oxide, VEGF, and VEGFR-2: Interactions in activity-induced angiogenesis in rat skeletal muscle. Am J Physiol Heart Circ Physiol 289: H336-H343.
59. Mirochnik Y, Kwiatek A, Volpert OV. 2008. Thrombospondin and apoptosis: Molecular mechanisms and use for design of complementation treatments. Curr Drug Targets 9: 851-862.
60. Morbidelli L, Donnini S, Ziche M. 2003. Role of nitric oxide in the modulation of angiogenesis. Curr Pharm Des 9: 521-530.
61. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, Fishman MC, et al. 1998. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101: 2567-2578.
62. Nabors LB, Fiveash JB, Markert JM, Kekan MS, Gillespie GY, Huang Z, JohnsonMJ, Meleth S, Kuo H, Gladson CL, et al. 2010. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol 67: 313-319.
63. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. 2008. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA 300: 2277-2285.
64. Nicosia RF, Tuszynski GP. 1994. Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol 124: 183-193.
65. Oganesian A, Armstrong LC, Migliorini MM, Strickland DK, Bornstein P. 2008. Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell 19: 563-571.
66. Olerud J, Johansson M, Lawler J, Welsh N, Carlsson PO. 2008. Improved vascular engraftment and graft function after inhibition of the angiostatic factor thrombospondin-1 in mouse pancreatic islets. Diabetes 57: 1870-1877.
67. Persson T, Lanshammar H, Medved V. 1995. A marker-free method to estimate joint centre of rotation by video image processing. Comput Methods Programs Biomed 46: 217-224.
68. Primo L, Ferrandi C, Roca C, Marchio S, di Blasio L, Alessio M, Bussolino F. 2005. Identification of CD36 molecular features required for its in vitro angiostatic activity. FASEB J 19: 1713-1715.
69. Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP, Campbell SC. 2002. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 98: 682-689.
70. Ren B, Song K, Parangi S, Jin T, Ye M, Humphreys R, Duquette M, Zhang X, Benhaga N, Lawler J, Khosravi-Far R. 2009. A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res 69: 3856-3865.
71. Ridnour LA, Isenberg JS, Espey MG, Thomas DD, Roberts DD, Wink DA. 2005. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci 102: 13147-13152.
72. Roberts DD, Isenberg JS, Ridnour LA, Wink DA. 2007. Nitric oxide and its gatekeeper thrombospondin-1 in tumor angiogenesis. Clin Cancer Res 13: 795-798.
73. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. 2001. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci 98: 12485-12490.
74. Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, MohapatraG, Figueiredo JL, Martuza RL, Weissleder R, Shah K. 2009. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci 106: 4822-4827.
75. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, et al. 2005. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7: 101-111.
76. Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter BR. 2005. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol 168: 643-653.
77. Simantov R, Febbraio M, Silverstein RL. 2005. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol 24: 27-34.
78. Streit M, Stephen AE, Hawighorst T, Matsuda K, Lange-Asschenfeldt B, BrownLF, Vacanti JP, Detmar M. 2002. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. Cancer Res 62: 2004-2012.
79. Sun J, Hopkins BD, Tsujikawa K, Perruzzi C, Adini I, Swerlick R, Bornstein P, Lawler J, Benjamin LE. 2009. Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. Am J Physiol Heart Circ Physiol 296: H1344-H1351.
80. Tan K, Duquette M, Liu JH, Dong Y, Zhang R, Joachimiak A, Lawler J, Wang JH. 2002. Crystal structure of the TSP-1 type 1 repeats: A novel layered fold and its biological implication. J Cell Biol 159: 373-382.
81. Taraboletti G, Roberts D, Liotta LA, Giavazzi R. 1990. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: A potential angiogenesis regulatory factor. J Cell Biol 111: 765-772.
82. Thakar CV, Zahedi K, Revelo MP, Wang Z, Burnham CE, Barone S, Bevans S, Lentsch AB, Rabb H, Soleimani M. 2005. Identification of thrombospondin 1 (TSP-1) as a novel mediator of cell injury in kidney ischemia. J Clin Invest 115: 3451-3459.
83. Tucker RP. 2004. The thrombospondin type 1 repeat superfamily. Int J Biochem Cell Biol 36: 969-974.
84. van Eekelen M, Sasportas LS, Kasmieh R, Yip S, Figueiredo JL, Louis DN, Weissleder R, Shah K. 2010. Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. Oncogene 29: 3185-3195.
85. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP. 2002. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 8: 349-357.
86. Wang S, Herndon ME, Ranganathan S, Godyna S, Lawler J, Argraves WS, Liau G. 2004. Internalization but not binding of thrombospondin-1 to low density lipoprotein receptor-related protein-1 requires heparan sulfate proteoglycans. J Cell Biochem 91: 766-776.
87. Wang Y, Wang S, Sheibani N. 2006. Enhanced proangiogenic signaling in thrombospondin-1-deficient retinal endothelial cells. Microvasc Res 71: 143-151.
88. Yamauchi M, Imajoh-Ohmi S, Shibuya M. 2007. Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle. Cancer Sci 98: 1491-1497.
89. Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, VolpertOV. 2005. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: A complementation antiangiogenic strategy. Clin Cancer Res 11: 6678-6685.
90. Yu J, deMuinck ED, Zhuang Z, Drinane M, Kauser K, Rubanyi GM, Qian HS, Murata T, Escalante B, Sessa WC. 2005. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci 102: 10999-11004.
91. Zaslavsky A, Chen C, Grillo J, Baek KH, Holmgren L, Yoon SS, Folkman J, Ryeom S. 2010. Regional control of tumor growth. Mol Cancer Res 8: 1198-1206.
92. Zhang X, Lawler J. 2007. Thrombospondin-based antiangiogenic therapy. Microvasc Res 74: 90-99.
93. Zhang X, Galardi E, Duquette M, Delic M, Lawler J, Parangi S. 2005. Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin Cancer Res 11: 2337-2344.
94. Zhang X, Connolly C, Duquette M, Lawler J, Parangi S. 2007. Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. Cancer Lett 247: 143-149.
95. Zhang X, Kazerounian S, Duquette M, Perruzzi C, Nagy JA, Dvorak HF, ParangiS, Lawler J. 2009. Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J 23: 3368-3376.